Chest
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The Milwaukee Protocol was used for a 24 year-old male U.S. soldier who was diagnosed with rabies after being bit by a feral dog in Afghanistan. He did not receive effective post exposure prophylaxis (PEP) for rabies however [1]. ⋯ Our case highlights the first time ECMO was used in rabies. Also, it exemplifies another failed case of the Milwaukee Protocol. Given the lack of efficacy, the protocol should not be used for rabies. A better understanding of rabies pathogenesis is needed in order to develop novel therapies.Reference #1: Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 2013 Jul;99(1):61-7.Reference #2: Willoughby,R et. Al Survival after Treatment of Rabies with Induction of Coma, N Engl J Med2005; 352:2508-2514DISCLOSURE: The following authors have nothing to disclose: Amritpal Nat, Amitpal Nat, Amit Sharma, Aravind Pothineni, Ioana AmzutaNo Product/Research Disclosure Information.
-
Lung Cancer Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Half of non-small cell lung cancers are diagnosed in locally advanced stages (LA-NSCLC) and treated by combining chemotherapy, radiation (RT), and surgery (S). Induction chemo (iCT) and chemoradiation (iCRT) are at least as effective as adjuvant therapies are, and allow to infer survival predictions depending on the grade of response. The 18-FDG-PET-CT-Scan (PET) is slowly introducing in the evaluation of those responses. We analyzed the impact of changes in re-staging PET in the outcome of patients with LA-NSCLC treated with induction therapies ⋯ Diego Marquez-Medina: Grant monies (from industry related sources): Llilly advisor, Grant monies (from industry related sources): Roche advisor, Grant monies (from industry related sources): Astra Zeneca speacher The following authors have nothing to disclose: Ariadna Gasol-Cudos, Antonio Martin-MarcoNo Product/Research Disclosure Information.
-
Bronchiectasis PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Bronchiectasis are defined as permanent, abnormal dilation of bronchi and bronchioles. Laenec in 1819, the first described them as a very common disease before the age of antibiotics. Today is a minor problem in developed countries in opposition to developing countries. The purpose of this study is to determine the prevalence of bacteria in patients with non-CF bronquiectacias. ⋯ The following authors have nothing to disclose: Georgina Gramblicka, Daniela Visentini, Valeria Morandi, Maria Laura Grodnitzky, Gabriela Tabaj, Patricia Malamud, Ana Sangoy, Andrea Appendino, Laura Biglieri, Silvia GuaycocheaNo Product/Research Disclosure Information.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The cryptogenic organizing pneumonia (COP) is a disease characterized by impairment of alveolar ducts and terminal bronchioles with inflammation. It was previously known as bronchiolitis obliterans organizing pneumonia (BOOP). It affects men and women with the same incidence and may be secondary to infections, drugs or be a primary manifestation. This case report presents a patient with COP whose approach dispensed, in accordance with the patient, lung biopsy for diagnosis. Only clinical data,laboratorial and image exams were used to define the conduct. ⋯ The patient improved dramatically after introduction of corticosteroid therapy, which has been decreasing gradually in posology. This case expresses an opportunity for choice by the patient, along with the physician and scientific evidence, to a personal approach for this disease.Reference #1: Vasu TS, Cavallazzi R, Hirani A, Sharma D, Weibel SB, Kane GC. Clinical and radiologic distinctions between secondary bronchiolitis obliterans organizing pneumonia and cryptogenic organizing pneumonia. Respir Care. 2009.Reference #2: Oymak FS, Demirbas HM, Mavili E, et al. Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration. 2005;723:254-262Reference #3: Sveinsson OA, Isaksson HJ, Sigvaldason A, Yngvason F, Aspelund T, Gudmundsson G. Clinical features in secondary and cryptogenic organising pneumonia. Int J Tuberc Lung Dis. 2009DISCLOSURE: The following authors have nothing to disclose: Gilmar Zonzin, Christian Boechat, Gabriela de Souza, Silvio Guerra, Priscila das Virgens, Jamile Abdalla, Vinícius AgostinhoNo Product/Research Disclosure Information.
-
Respiratory Infections PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Azithromycin (AZ) is a macrolide that has shown increased survival in patients with community-acquired pneumonia and bacteremic pneumococcal pneumonia. Immunomodulatory properties are claimed to be associated with the beneficial effects of macrolides. However, limited data are available about the clinical efficacy in patients with severe sepsis. Our aim was to assess the efficacy of AZ in addition to standard of care (SOC) therapy compared to SOC antimicrobial therapy in a pilot randomized controlled trial (RCT) in critically ill patients with severe sepsis. ⋯ Marcos Restrepo: Grant monies (from sources other than industry): NIH/NHLBI K23HL096054 The following authors have nothing to disclose: Paola Faverio, Alejandro Arango, Oriol Sibila, Eric Mortensen, Grant Waterer, Richard Wunderink, Antonio AnzuetoNo Product/Research Disclosure Information.